Artificial Intelligence

New data on MCO-010 gene therapy identifies ideal patients for Retinitis Pigmentosa, a key step as the one-time injection advances toward FDA approval.

The partnership moves beyond compliance, integrating deep binary analysis with lifecycle management to provide continuous software risk intelligence for critical industries.

Target Hospitality is rapidly expanding workforce housing for AI data centers, revealing the massive, unseen physical infrastructure powering the tech revolution.

Cullinan Therapeutics heads to key investor conferences, ready to showcase its T-cell engager platform for both cancer and challenging autoimmune diseases.

With pivotal data imminent for its blockbuster hopeful AXPAXLI, Ocular Therapeutix faces a critical month of investor meetings amid commercial headwinds.

Swiss biotech AC Immune begins a human trial for an oral drug aiming to halt the chronic inflammation driving diseases like Alzheimer's and Parkinson's.

With no approved therapies for Hepatitis E, Atea Pharmaceuticals' new drug shows potent preclinical results, offering a potential lifeline for vulnerable patients.

Blueprint Capital Advisors' new list of 'Active Icons' honors industry giants not just for wealth, but for their commitment to shaping a more inclusive future.

As Autolus heads to key investor conferences, its strong AUCATZYL® sales and deep pipeline face scrutiny against mounting losses and a curious PR misstep.

The Emerging Growth Conference showcases tomorrow's innovators. But with paid presentations, investors must look past the hype to find true value.

Riding a wave of 41% Q4 revenue growth and nearing profitability, the diagnostics firm will showcase its lung cancer solutions at two major conferences.

Khazna's new 100MW facility in Ajman, the MENA region's first certified liquid-cooled AI data center, signals a major leap in digital infrastructure.

With $1.2M in new funding, Validfor is unleashing agentic AI to tackle pharma's billion-dollar compliance problem and slash validation times.

Nokia and AWS launch a thinking 5G network with du and Orange. Their agentic AI promises to unlock the true business potential of network slicing.

A new screen protector promises glasses-free 3D on your iPhone. Can MOPIC succeed where tech giants have repeatedly failed?

Drilling at the Tesorito deposit has intersected a potential high-grade feeder zone, suggesting a much larger and richer system than previously modeled.

A new 'technology-only' law firm has been approved in the UK. Can its deterministic AI make legal help more affordable and consistent for everyone?

Avacta's pre|CISION therapy shows faster, more potent, and more selective tumor targeting than Enhertu in an AI-driven study, paving the way for 2026 trials.

A new partnership aims to unify the fragmented $4.7B MENA retail media market with AI, promising unprecedented efficiency for brands and retailers.

With key conferences ahead, Supernus Pharmaceuticals must prove its strategy can deliver growth in the competitive central nervous system drug landscape.